SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : RNAi
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who started this subject6/30/2004 5:51:09 PM
From: tom pope  Read Replies (1) of 671
 
VENLO, The Netherlands, June 30 /PRNewswire-FirstCall/ -- QIAGEN N.V. (NASDAQ: QGENF; Frankfurt, Prime Standard: QIA) a leading supplier of products and technologies for nucleic acid separation, purification and handling today announced that it has entered into a supply agreement for siRNA molecules with AstraZeneca (NYSE: AZN - News). Under the terms of this agreement QIAGEN will be the preferred supplier to AstraZeneca for siRNA products used in gene silencing applications. Financial terms were not disclosed.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News